- Conditions
- Frontotemporal Dementia
- Interventions
- Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 (OLE Treatment) - Placebo Switched to AL001
- Drug
- Lead sponsor
- Alector Inc.
- Industry
- Eligibility
- 25 Years to 85 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Location Directory
Clinical trials in Cincinnati, Ohio
This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10564
Shown on this page
12
Current sort
Recently updated
Location scope
Cincinnati, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1105–1116 of 10,564 matching trials in Cincinnati, OH.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Corneal Transplant Failure
- Interventions
- Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
- Procedure
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders
- Interventions
- Mirdametinib
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- COPD, COPD Exacerbation
- Interventions
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3,406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 276
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Foley, Alabama + 178 more
- Conditions
- High-risk Percutaneous Coronary Intervention
- Interventions
- Impella ECP
- Device
- Lead sponsor
- Abiomed Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Paramus, New Jersey + 1 more
- Conditions
- Nonalcoholic Steatohepatitis, Fibrosis
- Interventions
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- BMS-986489, Durvalumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 34
- States / cities
- Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more
- Conditions
- Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Interventions
- CBT, Amitriptyline
- Behavioral · Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 12 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0519-0130, Placebo, Trizepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 55
- States / cities
- Chula Vista, California • Fresno, California • Inglewood, California + 46 more
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
- Interventions
- VDyne Transcatheter Tricuspid Valve Replacement System
- Device
- Lead sponsor
- VDyne, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Detriot, Michigan • Minneapolis, Minnesota + 7 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Interventions
- TRX319, Bendamustine
- Biological · Drug
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more